62
Participants
Start Date
December 6, 2022
Primary Completion Date
September 30, 2024
Study Completion Date
September 30, 2024
B013+Nab-Paclitaxel
"B013 at a fixed dose of 600 milligrams via intravenous (IV) infusion on Days 1 and 15 of the first 28-day cycle, then on Day 1 of each subsequent 28-day cycle.~Nab-Paclitaxel 100 mg/m\^2 is administered weekly on Days 1, 8, 15 of each 28-day cycle."
Peking University Cancer Hospital, Beijing
Huai'an First People's Hospital, Huai'an
Tianjin medical university cancer institute&hospital, Tianjin
Zhejiang Cancer Hospital, Hangzhou
The Central Hospital of Yongzhou, Yongzhou
Xiangyang Central Hospital, Xiangyang
The First Affiliated Hospital of henan University of Science and Technoloy, Luoyang
Affiliated Cancer Hospital, Sun Yat-sen University, Guangzhou
Guangxi Medical University Cancer Hospital, Nanning
Hainan cancer Hospital, Haikou
Sichuan Cancer Hospital, Chengdu
The second people's hospital of neijiang, Neijiang
Yunnan Cancer Hospital, Kunming
Shanghai Pharmaceuticals Holding Co., Ltd
INDUSTRY
Shanghai Jiaolian Drug Research and Development Co., Ltd
INDUSTRY